Addiction center raises concerns over ketamine approval

A New Jersey, USA-based addiction treatment center has warned that the US regulator’s expected approval of ketamine to address depression could cause “an explosion in addiction.”

Last month US healthcare giant Johnson & Johnson (NYSE: JNJ) won a positive decision from the advisory panel of the US Food and Drug Administration on the firm’s experimental  depression therapy Spravato (esketamine).

Approval for the fast-acting antidepressant, which is administered through a nasal spray, is expected imminently.